1. Home
  2. BTAI vs SNTG Comparison

BTAI vs SNTG Comparison

Compare BTAI & SNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • SNTG
  • Stock Information
  • Founded
  • BTAI 2017
  • SNTG 2009
  • Country
  • BTAI United States
  • SNTG China
  • Employees
  • BTAI N/A
  • SNTG N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • SNTG Finance: Consumer Services
  • Sector
  • BTAI Health Care
  • SNTG Finance
  • Exchange
  • BTAI Nasdaq
  • SNTG Nasdaq
  • Market Cap
  • BTAI 6.6M
  • SNTG 5.9M
  • IPO Year
  • BTAI 2018
  • SNTG 2021
  • Fundamental
  • Price
  • BTAI $2.13
  • SNTG $1.87
  • Analyst Decision
  • BTAI Buy
  • SNTG
  • Analyst Count
  • BTAI 4
  • SNTG 0
  • Target Price
  • BTAI $37.00
  • SNTG N/A
  • AVG Volume (30 Days)
  • BTAI 279.4K
  • SNTG 430.5K
  • Earning Date
  • BTAI 03-11-2025
  • SNTG 12-17-2024
  • Dividend Yield
  • BTAI N/A
  • SNTG N/A
  • EPS Growth
  • BTAI N/A
  • SNTG N/A
  • EPS
  • BTAI N/A
  • SNTG N/A
  • Revenue
  • BTAI $2,276,000.00
  • SNTG $146,472.00
  • Revenue This Year
  • BTAI $105.36
  • SNTG N/A
  • Revenue Next Year
  • BTAI $46.93
  • SNTG N/A
  • P/E Ratio
  • BTAI N/A
  • SNTG N/A
  • Revenue Growth
  • BTAI 83.25
  • SNTG N/A
  • 52 Week Low
  • BTAI $2.10
  • SNTG $1.65
  • 52 Week High
  • BTAI $56.00
  • SNTG $3.97
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 28.68
  • SNTG 49.72
  • Support Level
  • BTAI $2.18
  • SNTG $1.71
  • Resistance Level
  • BTAI $2.60
  • SNTG $1.96
  • Average True Range (ATR)
  • BTAI 0.44
  • SNTG 0.10
  • MACD
  • BTAI -0.08
  • SNTG -0.00
  • Stochastic Oscillator
  • BTAI 0.94
  • SNTG 62.50

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About SNTG Sentage Holdings Inc.

Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.

Share on Social Networks: